Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Randomized double-blind placebo-controlled prospective, parallel, multicentre clinical trial of bacterial polivalent vaccine (BACTEK) administered by sublingual mucosa in subjects with chronic obstructive pulmonary disease (COPD) for efficacy evaluation, security and immunomodulatory response

X
Trial Profile

Randomized double-blind placebo-controlled prospective, parallel, multicentre clinical trial of bacterial polivalent vaccine (BACTEK) administered by sublingual mucosa in subjects with chronic obstructive pulmonary disease (COPD) for efficacy evaluation, security and immunomodulatory response

Status: Active, no longer recruiting
Phase of Trial: Phase III

Latest Information Update: 07 Feb 2024

Price : $35 *
  • Adis is an information provider.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
  • A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

  • Drugs MV 130 (Primary) ; MV 130 (Primary)
  • Indications Bacterial infections; Chronic obstructive pulmonary disease
  • Focus Registrational; Therapeutic Use
  • Sponsors Inmunotek
  • Most Recent Events

    • 04 May 2022 Planned End Date changed from 1 Mar 2022 to 1 Mar 2023.
    • 04 May 2022 Planned primary completion date changed from 1 Mar 2022 to 1 Mar 2023.
    • 01 Feb 2022 Planned End Date changed from 1 Dec 2020 to 1 Mar 2022.
Subscriber content

You need to be a logged in subscriber to view this content.

If your organization has a subscription then there are several options available to help you access AdisInsight, even while working remotely.

  • IP authentication when working within your organization’s network.
  • with username/password or try via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days.
  • Contact us at AsktheExpert.AdisInsight@springer.com for assistance.

If your organization does not have a subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Buy a PDF version of the profile.
  • Request a free trial
Back to top